Publication: Recent developments on dry eye disease treatment compounds
Loading...
Official URL
Full text at PDC
Publication Date
2014-01
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citations
Exportar
Abstract
Dry eye syndrome is a common tears and ocular surface multifactorial disease, described by changes in the ocular surface epithelia related to reduced tears quantity and ocular surface sensitivity, leading to inflammatory reaction. Managing the eye inflammation proved helpful to patients with dry eye disease and current treatment is based on the use of topically applied artificial tear products/lubricants, tear retention management, stimulation of tear secretion and using anti-inflammatory drugs. In this article we revise the corresponding literature and patents assembling the new treatment approaches of novel and future pharmaceutical compounds destined for the dry eye disease treatment. The most frequent categories of compounds presented are secretagogues and anti-inflammatory drugs. These compounds are the research outcome of novel therapeutic strategies designed to reduce key inflammatory pathways and restore healthy tear film.
Description
Open Access funded by King Saud University
Under a Creative Commons license
https://www.elsevier.com/journals/saudi-journal-of-ophthalmology/1319-4534/open-access-journal
UCM subjects
Unesco subjects
Keywords
Citation
1. Viso, E., Rodriguez-Ares, M.T., and Gude, F. Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study). Ophthalmic Epidemiol. 2009; 16: 15–21.
2. Moss, S.E., Klein, R., and Klein, B.E. Long-term incidence of dry eye in an older population. Optom Vis Sci. 2008; 85: 668–674.
3. Barker, K.E. and Savage, N.W. Burning mouth syndrome: an update on recent findings. Aust Dent J. 2005; 50: 220–223 (quiz 88).
4. Leiblum, S.R., Hayes, R.D., Wanser, R.A. et al. Vaginal dryness: a comparison of prevalence and interventions in 11 countries. J Sex Med. 2009; 6: 2425–2433.
5. Dartt, D.A. Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases. Prog Retin Eye Res. 2009; 28: 155–177.
6. Acosta, M.C., Peral, A., Luna, C. et al. Tear secretion induced by selective stimulation of corneal and conjunctival sensory nerve fibers. Invest Ophthalmol Vis Sci. 2004; 45: 2333–2336.
7. Belmonte, C., Aracil, A., Acosta, M.C. et al. Nerves and sensations from the eye surface. Ocul Surf. 2004; 2: 248–253.
8. Albietz, J.M. and Bruce, A.S. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res. 2001; 22: 8–18.
9. Yaguchi, S., Ogawa, Y., Kamoi, M. et al. Surgical management of lacrimal punctal cauterization in chronic GVHD-related dry eye with recurrent punctal plug extrusion. Bone Marrow Transplant. 2012; 47: 1465–1469.
10. Korb, D.R., Greiner, J.V., Glonek, T. et al. Effect of periocular humidity on the tear film lipid layer. Cornea. 1996; 15: 129–134.
11. Methodologies to diagnose and monitor dry eye disease. 2007 Report of the international dry eye workshop. Ocul Surf. 2007; 5: 108–152.
12. Luo, L., Li, D.Q., Corrales, R.M. et al. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Cont Lens. 2005; 31: 186–193.
13. Luo, L., Li, D.Q., Doshi, A. et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis sci. 2004; 45: 4293–4301.
14. Yang, C.Q., Sun, W., and Gu, Y.S. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006; 7: 675–678.
15. Bowling E, Russell GE. Topical Steroids and the treatment of dry eye. http://www.reviewofcontactlenses.com/content/d/dry_eye/c/27245/.2011.
16. Allergan. RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%. http://www.allergan.com/products/eye_care/restasis.htm2012.
17. Caceres V. Ocular surface, treating dry eye. http://www.eyeworld.org/article-treating-dry-eye2011.
18. Laurence, A., Pesu, M., Silvennoinen, O. et al. JAK kinases in health and disease: an update. Open Rheumatol J. 2012; 6: 232–244.
19. Darnell, J.E. Jr., Kerr, I.M., and Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (New York, NY). 1994; 264: 1415–1421.
20. Leonard, W.J. and Lin, J.X. Cytokine receptor signaling pathways. J Allergy Clin Immunol. 2000; 105: 877–888.
21. Scott, M.J., Godshall, C.J., and Cheadle, W.G. Jaks, STATs, cytokines, and sepsis. Clin Diagn Lab Immunol. 2002; 9: 1153–1159.
22. West, K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Invest Drugs (London, England: 2000). 2009; 10: 491–504.
23. Hirota, K., Duarte, J.H., Veldhoen, M. et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 2011; 12: 255– 263.
24. Kang, M.H., Kim, M.K., Lee, H.J. et al. Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Sci. 2011; 26: 938–944.
25. Brocker, C., Thompson, D., Matsumoto, A. et al. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics. 2010; 5: 30–55.
26. Barabino, S., Shen, L., Chen, L. et al. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005; 46: 2766–2771.
27. Garcia CK, Reddy S, Sieczkiewicz GJ, et al., IL-17 family cytokine compositions and uses, WO/2011/0445632011.
28. Adelman BA, Treating surface of the eye disorders. WO/2011/1634522011.
29. Kang SW, Cim CH, Composition for prevention or treatment of eye diseases, WO/2010/0475002010.
30. MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase). In: http://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=4318, editor. National Center for Biotechnology Information (NCBI)2013.
31. Sisto, M., Lisi, S., Lofrumento, D.D. et al. Sjogren’s syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-kappaB. Genes Immun. 2012; 13: 411–420.
32. Hong BS, Meadows DL, Methods and compositions for treating dry eye. WO/2009/0649832009.
33. Nagelhout, T.J., Gamache, D.A., Roberts, L. et al. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J Ocul Pharmacol Ther. 2005; 21: 139–148.
34. Sambursky, R. and O’Brien, T.P. MMP-9 and the perioperative management of LASIK surgery. Curr Opin Ophthalmol. 2011; 22: 294–303.
35. Rodgers JD, Shepard S, Li YL, et al., Azetidine and cyclobutane derivatives as JAK inhibitors. WO/2009/1145122009.
36. Friedman PA, Friedman JS, Luchi ME, et al., Janus kinase inhibitors for treatment of dry eye and other eye related diseases, US200611637545, WO/2010/039939, US201001134162010.
37. Rodgers JD, Shepard S, Azetidine and cyclobutane derivatives as JAK inhibitors, US201281586162012.
38. Ferguson-Smith, A.C., Chen, Y.F., Newman, M.S. et al. Regional localization of the interferon-beta 2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21. Genomics. 1988; 2: 203–208.
39. Li H, Heckrodt TJ, Chen Y, et al., Compositions and methods for inhibition of the JAK pathway. WO/2010/0856842010.
40. Taylor V, Li H, Singh R, Compositions and methods for inhibition of the JAK pathway. WO/2011/0171782011.
41. Li H, Heckrodt TJ, Chen Y, et al., Compositions and methods for inhibition of the JAK pathway. WO/2012/0159722012.
42. Dana R, Chauhan S, Therapeutic compositions for treatment of ocular inflammatory disorders, WO/2009/0890362009.
43. Rouvier, E., Luciani, M.F., and Golstein, P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med. 1993; 177: 195–200.
44. Miossec, P. and Kolls, J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Dis. 2012; 11: 763–776.
45. Quiniou C, Chemtob S, Barney S, Allosteramers for TNF receptors and uses. WO/2010/124259 2010.
46. Kaufmann M, Barney S, Methods of identification of allosteramers. WO/2010/1242622010.
47. Massingale, M.L., Li, X., Vallabhajosyula, M. et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 2009; 28: 1023–1027.
48. Tzu, J.H., Utine, C.A., Stern, M.E. et al. Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. Cornea. 2012; 31: 649–654.
49. Anglade, E., Yatscoff, R., Foster, R. et al. Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opin Investig Drugs. 2007; 16: 1525–1540.
50. Mitra A, Valagaleti PR, Natesan S, Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors. US2008/0791702008.
51. Schirra, F., Seitz, B., Knop, N. et al. Sex hormones and dry eye. Ophthalmologe. 2009; 106: 988–994.
52. Mostafa, S., Seamon, V., and Azzarolo, A.M. Influence of sex hormones and genetic predisposition in Sjogren’s syndrome: a new clue to the immunopathogenesis of dry eye disease. Exp Eye Res. 2012; 96: 88–97.
53. Dalton JT, Miller DD, SARMS and method of use thereof. US201077724332010.
54. Dalton JT, Miller DD, Substituted acylanilides and methods of use thereof. US201180806822011.
55. Dalton JT, Miller DD, Rakov I, et al., Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof. US201181105622011.
56. Dalton JT, Barrett C, He Y, et al., Nuclear receptor binding agents. US201281588282012.
57. Zhi L, Selective androgen receptor modulators (SARMS) and uses thereof, WO/2009/082437 2009.
58. Varchi G., Guerrini A., Brigliadori G, et al., Selective androgen receptor modulators (SARMS). WO/2010/0925462010.
59. Varchi G, Tesei A, Brigliadori G, Non-steroidal compounds for androgen receptor modulation. WO/2010/1163422010.
60. Aberg AKG, inventorTreating xerophthalmia with compounds increasing meibomian gland secretion. R-salbutamol for ocular indications is preferably administered by instillation to the eye or into the conjunctival sac. WO/2011/0687862011.
61. Schlienger N, Thygesen MB, Pawlas J, et al., Aminophenyl derivatives as selective androgen receptor modulators. US200975858772009.
62. Ousler III GW, Chapin MJ, Abelson MB, Formulations and methods for treating dry eye. WO/2008/1537462008.
63. Uldam HK, Thygesen MB, N-substituted piperidine derivatives as serotonin receptor agents. WO/2009/0394612009.
64. Schlienger N, Thygesen M, Uldam HK, et al., N-substituted piperidine derivatives as serotonin receptor agents. WO/2010/1113532010.
65. Moulignier, A. Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications. Rev Neurol (Paris). 1994; 150: 3–15.
66. Boullin, D.J. and Glenton, P.A. Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine. Br J Pharmacol. 1978; 62: 537–542.
67. Oh U, Cho HW, Yang YD, et al., Method of identifying agents which modulate the activity of calcium activated chloride channel. WO/2009/0514392009.
68. Goyal, S., Chauhan, S.K., El Annan, J. et al. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?. Arch Ophthalmol. 2010; 128: 819–824.
69. Dana R, Chauhan S, Therapeutic compositions for the treatment of dry eye disease. WO/2011/1066972011.
70. Goyal, S., Chauhan, S.K., and Dana, R. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease. Arch Ophthalmol. 2012; 130: 84–89.
71. Aberg AKG, Johnson K, Treating xerophthalmia with Norketotifen. WO/2010/0476812010.
72. Aberg AKG, Johnson K, Ocular formulations of Norketotifen. WO/2010/0598942010.
73. Milner, E., Sousa, J., Pybus, B. et al. Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy. Eur J Drug Metab Pharmacokinet. 2012; 37: 17–22.
74. Ramsden N, Major J, Morel A, et al., Pyrimidine derivatives as ZAP-70 inhibitors. WO/2010/1427662010.
75. Major J, Piton N, Sulfonamides and sulfamides as ZAP-70 inhibitors. WO/2010/1461322010.
76. Sunose M, Major J, Harrison RJ, et al., Heterocyclylaminopyrimidines as kinase inhibitors. WO/2010/1461332010.
77. Fischer, A., Picard, C., Chemin, K. et al. ZAP70: a master regulator of adaptive immunity. Semin Immunopathol. 2010; 32: 107–116.
78. Elder, M.E. ZAP-70 and defects of T-cell receptor signaling. Semin Hematol. 1998; 35: 310–320.
79. Negishi, I., Motoyama, N., Nakayama, K. et al. Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature. 1995; 376: 435–438.
80. Nakajima T, Nakajima T, Azuma M, Partial peptide of lacritin. WO/2011/0342072011.
81. Karnati, R., Laurie, D.E., and Laurie, G.W. Lacritin and the tear proteome as natural replacement therapy for dry eye. Exp Eye Res. 2013.
82. Cha S, Pauley KM, Targeted receptor-mediated siRNA. WO/2012/0060832012.
83. Michael J. Dart, Philip R. Kym, Eric A. Voight, et al., Trpv1 antagonists. WO20130962262013.
84. Martinez, T., Wright, N., Lopez-Fraga, M. et al. Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet. 2013; 132: 481–493.
85. V. G., J. M-M, Sádaba B., et al., editors. SYL1001 for Treatment of Ocular Discomfort in Dry Eye: Safety and Tolerance (Phase I Study). ARVO 2012; 2012.
86. Carracedo, G., Peral, A., and Pintor, J. Diadenosine polyphosphates in tears of Sjogren syndrome patients. Invest Ophthalmol Vis Sci. 2010; 51: 5452–5459.
87. Pintor, J. A molecular marker for dry eye. Archivos de la Sociedad Espanola de Oftalmologia. 2007; 82: 129–130.
88. McGinnigle, S., Naroo, S.A., and Eperjesi, F. Evaluation of dry eye. Surv Ophthalmol. 2012; 57: 293–316.
89. Lemp, M.A., Bron, A.J., Baudouin, C. et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011; 151 (792-8 e1).